Emerald card is Awesome 🤝Solayer (@solayer_labs):Introducing Emerald Sub Cards:one account, unlimited cardscustom labels, individual limits, and spending tracking all available in one https://t.co/I0r8yohDcA ...

Lotus Technology (LOT) Q1 2025 Earnings Call June 25, 2025 08:00 AM ET Company Participants Demi Zhang - Head of Investor Relations, Board Secretary Office, ESG Committee & Disclosure Committee MemberDaxue Wang - CFO Operator Day, and thank you for standing by. Welcome to Lotus Technology Inc. First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. Please be advised that today's conference is being recorded. I would now like to hand the conference ...

Lotus Technology (LOT) Q1 2025 Earnings Call June 25, 2025 08:00 AM ET Speaker0 Day, and thank you for standing by. Welcome to Lotus Technology Inc. First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. Please be advised that today's conference is being recorded. I would now like to hand the conference over to Ms. Demi Zhang from the company. Please go ahead. Speaker1 Thank you, operator. Good morning, good afternoon, and good evening, everyone. ...

撰文丨王聪 编辑丨王多鱼 排版丨水成文 近日，美国 费城儿童医院和宾夕法尼亚大学医学院的研究团队取得了 一项具有里程碑意义的医学突破 —— 人类首次实现为单个病人定制基因编辑疗法 ，并成功治疗了一名 患有罕见致命遗传疾病的婴儿。 该研究以： Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease 为题，于 2025 年 5 月 15 日发表在了《 新英格兰医学杂志 》 （NEJM） ，详细介绍了这款定制的 体内碱基编辑疗法 的开 发和治疗过程。 这一具有里程碑意义的成功案例可能为基因编辑技术开辟一条成功应用于治疗那些目前尚无医疗手段可用 的罕见病患者的新途径。 婴儿 KJ Muldoon 在出生几天后就被诊断出患有严重的 氨甲酰磷酸合成酶-1 （CPS1） 缺乏症 ，这是一 种罕见且严重的隐性遗传疾病 （在新生儿中发病率为130万分之一） ，是最严重的 尿素循环障碍 疾病。 人体在分解蛋白质时会产生 氨 ，正常情况下，我们的身体会将氨转化为 尿素 ，然后通过排尿将尿素排出 体外。 CPS1 作为一种线粒体酶， 催化尿素循环的第 ...

该研究以： Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease 为题，于 2025 年 5 月 15 日发表在了《 新英格兰医学杂志 》 （NEJM） ，详细介绍了这款定制的 体内碱基编辑疗法 的开 发和治疗过程。 这一具有里程碑意义的成功案例可能为基因编辑技术开辟一条成功应用于治疗那些目前尚无医疗手段可用 的罕见病患者的新途径。 撰文丨王聪 编辑丨王多鱼 排版丨水成文 近日， 费城儿童医院和宾夕法尼亚大学医学院的研究团队取得了一项具有里程碑意义的医学突破—— 人类 首次实现为单个病人定制基因编辑疗法 ，并成功治疗了一名 患有罕见致命遗传疾病的儿童。 婴儿 KJ 在出生几天后就被诊断出患有严重的 氨甲酰磷酸合成酶-1 （CPS1） 缺乏症 ，这是一种罕见且 严重的遗传疾病 （在新生儿中发病率为130万分之一） ，是最严重的 尿素循环障碍 疾病。 KJ 与为他开发疗法的研究人员在一起 人体在分解蛋白质时会产生 氨 ，正常情况下，我们的身体会将氨转化为 尿素 ，然后通过排尿将尿素排出 体外。然而，患有尿素循环障碍的儿童肝脏中缺 ...

Spectrum Brands (SPB) Q2 2025 Earnings Call May 08, 2025 09:00 AM ET Company Participants Joanne Chomiak - Director of Investor RelationsDavid Maura - Executive Chairman & CEOJeremy Smeltser - Executive VP & CFOPeter Lukas - DirectorOlivia Tong - Managing Director Conference Call Participants Peter Grom - Equity Research Analyst Operator Good day, and thank you for standing by. Welcome to the Q2 twenty twenty five Spectrum Brands Holding Earnings Conference Call. At this time, all participants are in a list ...

Spectrum Brands (SPB) Q2 2025 Earnings Call May 08, 2025 09:00 AM ET Speaker0 Good day, and thank you for standing by. Welcome to the Q2 twenty twenty five Spectrum Brands Holding Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone. You will then hear an automated message advising that your hand is raised. To withdraw ...

TeaPot Launches New 10mg THC Rosin-Infused Iced Tea, while Emerald Hour Expands Into British Columbia and Adds Two New Cannabis Cocktail Styles TeaPot TeaPot Introduces Rosin-Infused Iced Tea with 10mg of THC Emerald Hour Emerald Hour Adds Two New Cocktail Recipes and Expands into British Columbia TORONTO, May 08, 2025 (GLOBE NEWSWIRE) -- BBCCC Inc, the Canadian-based subsidiary of The Boston Beer Company, is elevating summer for Canadians with new offerings from its cannabis brands TeaPot and Emeral ...

Core Insights - Hudson Technologies, Inc. reported a revenue of $55.3 million for Q1 2025, a decrease of 15% compared to $65.3 million in Q1 2024, primarily due to lower refrigerant prices despite a slight increase in sales volume [9][16] - The gross margin for Q1 2025 was 22%, down from 33% in the same period last year, largely driven by price compression in the refrigerant market [9][16] - The company has a strong balance sheet with $81 million in cash and no debt as of March 31, 2025, and has repurchased $4.5 million of common stock in 2025 [4][8] Financial Performance - Revenues for Q1 2025 were $55.3 million, down 15% from $65.3 million in Q1 2024 [9][16] - Gross profit decreased to $12.1 million in Q1 2025 from $21.4 million in Q1 2024, reflecting the decline in gross margin [9][16] - Operating income fell to $3.1 million in Q1 2025 from $12.8 million in the prior year [9][16] - Net income for Q1 2025 was $2.8 million, or $0.06 per share, compared to $9.6 million, or $0.21 per share, in Q1 2024 [9][16] Market and Strategic Insights - The company anticipates continued growth in its reclamation business due to the phase-down of HFC refrigerants under the AIM Act, which is expected to reduce the supply of virgin HFCs [3] - Several states are implementing requirements for the use of reclaimed refrigerants in municipal buildings, creating additional demand opportunities [3] - Hudson Technologies is focused on responsible refrigerant management and has strengthened its capabilities through the acquisition of USA Refrigerants [2][3] Cash Flow and Capital Allocation - Cash provided by operating activities was $14.2 million in Q1 2025, compared to a cash used of $0.9 million in the same period last year [19] - The company invested $1.4 million in property, plant, and equipment during the quarter [20] - Hudson Technologies continues to pursue a capital allocation strategy that includes organic growth investments, acquisitions, and stock repurchases [4][8]

— Delivered Revenue Growth of 4%, Net Income Growth of 5%, and EPS Growth of 9% — KANSAS CITY, Mo., May 07, 2025 (GLOBE NEWSWIRE) -- H&R Block, Inc. (NYSE: HRB) (the "Company") today released financial results for its fiscal 2025 third quarter ended March 31, 2025. — Improved Volume and Market Share Trends in Assisted Channel Through April 30 — "Today we are reaffirming our FY25 outlook," said Jeff Jones, president and chief executive officer. "Our transformation continues to gather momentum and deliver res ...